Akums Drugs and Pharmaceuticals Ltd
Thu 13/03/2025,15:57:44 | NSE : AKUMS
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 515.00
Previous Close
₹ 517.20
Volume
133626
Mkt Cap ( Rs. Cr)
₹8031.03
High
₹ 520.65
Low
₹ 506.40
52 Week High
₹ 1175.90
52 Week Low
₹ 432.60
Book Value Per Share
₹ 180.08
Dividend Yield
0.00
Face Value
₹ 2.00
What’s Your Call?
Collective community sentiment on Akums Drugs and Pharmaceuticals Ltd
Your Vote -
Buy
69.57%
Hold
17.39%
Sell
13.04%
69.57%
23 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
NaN%
Sell Order Quantity
NaN%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Akums Drugs and Pharmaceuticals Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Akums Drugs & Pharma - Analysts/Institutional Investor Meet/Con. Call Updates
-
Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Akums Drugs & Pharma - Analysts/Institutional Investor Meet/Con. Call Updates
-
Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Akums Drugs & Pharma - Copy of Newspaper Publication
-
Akums Drugs & Pharma - General Updates
-
Akums Drugs & Pharma - Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure
-
Akums Drugs & Pharma - Shareholders meeting
-
Akums Drugs & Pharma - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
-
Akums Drugs & Pharma - Analysts/Institutional Investor Meet/Con. Call Updates
-
Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Akums Drugs & Pharma - Monitoring Agency Report
-
Akums Drugs & Pharma - Analysts/Institutional Investor Meet/Con. Call Updates
-
Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
-
Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
-
Akums Drugs & Pharma - Analysts/Institutional Investor Meet/Con. Call Updates
-
Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
-
Akums Drugs & Pharma - Statement Of Deviation.
-
Akums Drugs & Pharma - Integrated Filing (Financial)
-
Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Investor Presentation
-
Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Akums Drugs & Pharma - Un-Audited Financial Results For The Quarter And Nine Months Ended December 31, 2024.
-
Akums Drugs & Pharma - Copy of Newspaper Publication
-
Akums Drugs & Pharma - Integrated Filing- Financial
-
Akums Drugs & Pharma - Statement of deviation(s) or variation(s) under Reg. 32
-
Akums Drugs & Pharma - Investor Presentation
-
Akums Drugs & Pharma - Statement Of Deviation
-
Akums Drugs & Pharma - Press Release
-
Akums Drugs & Pharma - Integrated Filing (Financial)
-
Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Investor Presentation
-
Akums Drugs & Pharma - Financial Result Updates
-
Akums Drugs & Pharma Q3 net profit jumps 40.32% at Rs 41.17 cr
-
Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Akums Drugs & Pharma - Outcome of Board Meeting
-
Akums Drugs & Pharma - Outcome Of Board Meeting Held On 06Th February, 2025.
-
Akums Drugs & Pharma - Board Meeting Outcome for Outcome Of Board Meeting Held On 06Th February, 2025
-
Akums Drugs & Pharma - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Akums Drugs & Pharma - Updates
-
Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Cessation
-
Akums Drugs & Pharma - Analysts/Institutional Investor Meet/Con. Call Updates
-
Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Akums Drugs & Pharma - Board Meeting Intimation
-
Akums Drugs & Pharma - Board Meeting Intimation for Approval Of Un-Audited Financial Results For The Quarter And Nine Months
-
Akums Drugs & Pharma - Update On Income Tax Search
-
Akums Drugs & Pharma - Updates
-
Akums Drugs & Pharma - Updates
-
Akums Drugs & Pharma - Income Tax Search
-
Akums Drugs & Pharma - Updates
-
Akums Drugs & Pharma - Change Of Name Of RTA
-
Akums Drugs & Pharma - Trading Window-XBRL
-
Akums Drugs & Pharma - Trading Window
-
Akums Drugs & Pharma - Agreements,Contracts,Arrangements,MOU-XBRL
-
Akums Drugs & Pharma - Agreements
-
Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
-
Akums Drugs & Pharma - Shareholders meeting
-
Akums Drugs & Pharma - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report
Key fundamentals
Evaluate the intrinsic value of Akums Drugs and Pharmaceuticals Ltd stock
Name | March-24 | ||||
---|---|---|---|---|---|
Assets | 370.164 | ||||
Liabilities | 370.164 | ||||
Equity | 28.613 | ||||
Gross Profit | -126.658 | ||||
Net Profit | -165.451 | ||||
Cash From Operating Activities | 247.907 | ||||
NPM(%) | -11.45 | ||||
Revenue | 1444.119 | ||||
Expenses | 1570.777 | ||||
ROE(%) | -5.83 |
Corporate Action
XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
---|
Peers
Other companies within the same industry or sector that are comparable to Akums Drugs and Pharmaceuticals Ltd
Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
---|---|---|---|---|---|---|
Albert David Ltd | 808.20 | -1.14 | 11.41 | 291.38 | 1321.50 | 1.42 |
Lotus Eye Hospital and Institute Ltd | 57.06 | -0.77 | 237.75 | 1061.76 | 14.01 | 0.88 |
Vaishali Pharma Ltd | 12.12 | -5.90 | 606.00 | 547.27 | 2.31 | 0.00 |
Astec Lifesciences Ltd | 653.90 | -5.55 | 0.00 | 1001.14 | -239.30 | 0.00 |
Company Info
Our Company was incorporated as a public limited company under the Companies Act, 1956 as `Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the RoC. Our Company received a certificate for commencement of business issued by the RoC dated May 13, 2004.Major Events and Milestones:2004-Incorporation of the Company-Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand2007-Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand2009-Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals2010-Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Incorporated Akumentis Healthcare Limited to venture into branded formulations2011-Innovated bi-layered sustained release tablets for the first time2012-Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities2013-Innovated tablet-in-tablet sustained release tablets for the first time-Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities-Expanded into the African market2015-Expanded into the Asian market-Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market2016-Maxcure Nutravedics Limited received US-NSF certification2019-Investment by Ruby QC Investment Holdings Pte. Ltd. in our Company to become a minority shareholder2021-Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs-Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited2022-Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets-Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited2023-Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited-Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited
Our Company was incorporated as a public limited company under the Companies Act, 1956 as `Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the RoC. Our Company received a certificate for commencement of business issued by the RoC dated May 13, 2004.Major Events and Milestones:2004-Incorporation of the Company-Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand2007-Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand2009-Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals2010-Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Incorporated Akumentis Healthcare Limited to venture into branded formulations2011-Innovated bi-layered sustained release tablets for the first time2012-Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities2013-Innovated tablet-in-tablet sustained release tablets for the first time-Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities-Expanded into the African market2015-Expanded into the Asian market-Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market2016-Maxcure Nutravedics Limited received US-NSF certification2019-Investment by Ruby QC Investment Holdings Pte. Ltd. in our Company to become a minority shareholder2021-Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs-Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited2022-Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets-Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited2023-Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited-Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited
Read More
Parent Organisation
Akums Drugs & Pharmaceuticals Ltd.
Founded
19/04/2004
Managing Director
Mr.Sanjeev Jain
NSE Symbol
AKUMSEQ
FAQ
The current price of Akums Drugs and Pharmaceuticals Ltd is ₹ 510.25.
The 52-week high for Akums Drugs and Pharmaceuticals Ltd is ₹ 520.65 and the 52-week low is ₹ 506.40.
The market capitalization of Akums Drugs and Pharmaceuticals Ltd is currently ₹ 8031.03. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Akums Drugs and Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Akums Drugs and Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Akums Drugs and Pharmaceuticals Ltd shares.
The CEO of Akums Drugs and Pharmaceuticals Ltd is Mr.Sanjeev Jain, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.